Wall Street analyst estimates for Pyxis Oncology, Inc. (PYXS): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Pyxis Oncology, Inc. operates as a preclinical biopharmaceutical company focused on developing novel therapeutic approaches to combat various forms of cancer. Its investigational immune-oncology pipeline includes PYX-106, a fully human immunoglobulin G1 (IgG1) antibody designed to target siglec-15, which is being explored for its potential efficacy against thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 8 |
| Hold | 2 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 10 |
| Avg rating (1-5) | 0.80 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-02 | $-0.27 | ||
| 2026-08-13 | $-0.40 | $-0.35 | -14.3% |
| 2026-05-14 | $-0.37 | $-0.35 | -5.7% |
| 2026-03-23 | $-0.29 | $-0.35 | +17.1% |
| 2025-11-03 | $-0.35 | $-0.36 | +2.8% |
| 2025-08-14 | $-0.30 | $-0.36 | +16.7% |
| 2025-05-15 | $-0.35 | $-0.29 | -20.7% |
| 2025-03-18 | $-0.58 | $-0.33 | -75.8% |
Valuation Ratios
| Price / Book | 19.38 |
| EV / EBITDA | -2.94 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | $16.1M | $13.9M |
| Cost of Revenue | 0 | $444000 | 0 | 0 | 0 | $475000 | $2.4M |
| Gross Profit | 0 | -$444000 | 0 | 0 | 0 | $15.7M | $11.5M |
| Research & Development | $1.2M | $8.6M | $51.1M | $86.1M | $49.6M | $58.7M | $73.7M |
| Selling, General & Admin | $1.7M | $3.8M | $18.7M | $37.4M | $32.6M | $25.4M | $22.2M |
| Operating Expenses | $2.9M | $12.4M | $69.7M | $123.5M | $82.2M | $105.1M | $95.9M |
| Operating Income | -$2.9M | -$12.9M | -$69.7M | -$123.5M | -$82.2M | -$89.5M | -$84.4M |
| EBITDA | -$2.8M | -$12.4M | -$75.3M | -$120.0M | -$71.9M | -$65.5M | -$73.7M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pre-tax Income | -$2.8M | -$12.8M | -$76.0M | -$120.7M | -$73.8M | -$79.5M | -$78.2M |
| Income Tax | 0 | 0 | 0 | 0 | 0 | -$2.2M | $1.4M |
| Net Income | -$2.8M | -$12.8M | -$76.0M | -$120.7M | -$73.8M | -$77.3M | -$79.6M |
| EPS | $-0.08 | $-0.37 | $-2.53 | $-3.57 | $-1.85 | $-1.32 | $-1.28 |
| EPS (Diluted) | $-0.08 | $-0.37 | $-2.53 | $-3.57 | $-1.85 | $-1.32 | $-1.28 |
| Shares Outstanding (Diluted) | $34.3M | $34.3M | $32.2M | $33.0M | $39.9M | $58.4M | $62.1M |
Price
| Price | $3.34 |
| Market Cap | $212M |
| Exchange | NASDAQ |
| Country | US |
Related companies: AVIR · CRBU · ENTA · FHTX · HUMA · IMRX · TNYA
Explore sector: Healthcare · Biotechnology
More sections of PYXS: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks